Skip to main content

Advertisement

SpringerLink
Log in

PET Imaging of Hepatocellular Carcinoma

  • NUCLEAR MEDICINE & PET/CT IMAGING (R FLAVELL, SECTION EDITOR)
  • Published:
Current Radiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Positron emission tomography has not traditionally played a major role in the evaluation of hepatocellular carcinoma (HCC). Owing to high background liver uptake and molecular mechanisms within HCC lesions, uptake of 18F-fluorodeoxyglucose (FDG) is variable and prior studies have shown only modest overall detection of intrahepatic disease.

Recent Findings

Tracers such as 18F- and 11C-choline as well as 11C-acetate have been explored either in isolation or together with 18F-FDG have shown greater promise in detection of intrahepatic lesions, but yet are not in widespread clinical use. 68 Ga-Prostate specific membrane antigen is a tracer developed for use in prostate cancer but a pilot study and several case reports have indicated that there may be the potential for use in the evaluation of HCC.

Summary

Increased rates of lesion detection using 18F-FDG may be seen in poorly differentiated tumors and in the setting of metastatic disease or within recurrent tumor following loco-regional therapies and FDG uptake may indicate a greater risk of recurrence following transplantation. Further work will be required to elucidate the precise role of other non FDG tracers in the evaluation of patients at risk for or with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Global Cancer Observatory. http://globocan.iarc.fr/Default.aspx (2018). Accessed 25 Jan 2019.

  2. Makarova-Rusher OV, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757–65.

    Article  Google Scholar 

  3. Heimbach JK, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  Google Scholar 

  4. Galle PR, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Article  Google Scholar 

  5. Kokudo N, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015. https://doi.org/10.1111/hepr.12464.

    Article  PubMed  Google Scholar 

  6. Chernyak V, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–30.

    Article  Google Scholar 

  7. Wald C, et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Oak Brook: Radiological Society of North America Inc.; 2013.

    Google Scholar 

  8. Trojan J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94(11):3314–9.

    Article  CAS  Google Scholar 

  9. Khan MA, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32(5):792–7.

    Article  CAS  Google Scholar 

  10. Wudel LJ Jr, et al. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma/discussion. Am Surg. 2003;69(2):117.

    PubMed  Google Scholar 

  11. Lin W-Y, Tsai S-C, Hung G-U. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26(4):315–21.

    Article  Google Scholar 

  12. Torizuka T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36(10):1811.

    CAS  PubMed  Google Scholar 

  13. Salem N, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-d-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007;9(3):135–43.

    Article  Google Scholar 

  14. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12(7):413–39.

    Article  CAS  Google Scholar 

  15. Yamamoto Y, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49(8):1245–8.

    Article  Google Scholar 

  16. Talbot J-N, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51(11):1699–706.

    Article  Google Scholar 

  17. Kolthammer JA, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38(7):1248–56.

    Article  CAS  Google Scholar 

  18. Grassi I, et al. The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging. 2012;2(1):33.

    CAS  PubMed  Google Scholar 

  19. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44(2):213–21.

    PubMed  Google Scholar 

  20. Park JW, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49(12):1912–21.

    Article  Google Scholar 

  21. Rauscher I, et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16(1):14.

    Article  Google Scholar 

  22. • Huang HL, Zhen Loh TJ, Hoe Chow PK. A case of well-differentiated hepatocellular carcinoma identified on gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography. World J Nucl Med. 2018;17(2):102–05. Case reports demonstrating focal 68 Ga-PSMA uptake in HCC.

  23. • Sasikumar A, et al. 68 Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(4):795–96. Case reports demonstrating focal 68 Ga-PSMA uptake in HCC.

  24. •• Kesler M, et al. (68)Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med 2018. Pilot study demonstrating high sensitivity for HCC using 68 Ga-PSMA.

  25. Katyal S, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216(3):698–703.

    Article  CAS  Google Scholar 

  26. Sugiyama M, et al. 18 F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39(10):961–8.

    Article  CAS  Google Scholar 

  27. Wu H-B, et al. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36(12):1092–7.

    Article  Google Scholar 

  28. Ho C-L, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48(6):902.

    Article  CAS  Google Scholar 

  29. Lopci E, et al. Diagnostic accuracy of 11 C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2015;42(9):1399–407.

    Article  CAS  Google Scholar 

  30. Paudyal B, et al. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep. 2007;18(6):1469–73.

    CAS  PubMed  Google Scholar 

  31. Han A-R, et al. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation following interventional therapy for hepatocellular carcinom. Hepatogastroenterology. 2009;56(93):1111–6.

    PubMed  Google Scholar 

  32. Lee JW, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50(5):682–7.

    Article  Google Scholar 

  33. Yang SH, et al. The role of 18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006;12(11):1655–60.

    Article  Google Scholar 

  34. Lee SD, et al. 18F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26(1):50–60.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deparment of Radiology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA

    Eric C. Ehman, Scott M. Thompson, Brian T. Welch & Derek R. Johnson

  2. Department of Medical Imaging, University of Arizona, 1501 N. Campbell Rd, Tucson, AZ, 85724, USA

    Hugh C. J. McGregor

Authors
  1. Eric C. Ehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott M. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian T. Welch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Derek R. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hugh C. J. McGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric C. Ehman.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Nuclear Medicine & PET/CT Imaging.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ehman, E.C., Thompson, S.M., Welch, B.T. et al. PET Imaging of Hepatocellular Carcinoma. Curr Radiol Rep 7, 18 (2019). https://doi.org/10.1007/s40134-019-0329-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s40134-019-0329-5

Keywords

Search

Navigation